你即將離開本站

並前往https://www.cna.com.tw/postwrite/detail/261615

INBUILD® meets primary endpoint | 中央社訊息平台 - 中央社

... Germany -- (BUSINESS WIRE) -- Boehringer Ingelheim announced today that in the Phase III INBUILD® trial nintedanib slowed lung function ...

確定！ 回上一頁

查詢 「INBUILD trial」的人也找了：

  1. INBUILD trial
    2.
  2. SENSCIS trial
    3.
  3. Nintedanib clinical trial
    4.
  4. pf-ild definition
    5.
  5. Pirfenidone
    6.
  6. TOMORROW trial
    7.
  7. RELIEF pirfenidone
    8.
  8. Progressive fibrosing interstitial lung disease
    9.